NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts
NCT01902225 2020-06-09Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaUniversity of California, San FranciscoPhase 1 Completed24 enrolled
NCT01490047 2015-06-16Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or LymphomasLudwig Institute for Cancer ResearchPhase 1 Withdrawn